Brief: FDA Approves Pfizer Inc's Palbociclib Combo for HR-positive, HER2-positive metastatic breast cancer Maintenance
24/06/2026 16:48
BRIEF-FDA Approves Pfizer Inc's Palbociclib Combo for HR-positive, HER2-positive metastatic breast cancer Maintenance June 24 (Reuters) - FDA:
FDA APPROVES PALBOCICLIB WITH TRASTUZUMAB, WITH OR WITHOUT PERTUZUMAB, AND ENDOCRINE THERAPY FOR THE MAINTENANCE TREATMENT OF HR-POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER
Further company coverage: PFE.N
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials